• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Erin M. Sullivan Joins Abt Bio-Pharma Solutions, Inc., As Senior Director, Reimbursement & Health Economics

Posted on: Tuesday, 7 October 2008, 12:00 CDT

LEXINGTON, Mass., Oct. 7 /PRNewswire/ -- Erin M. Sullivan, M.P.H., Ph.D., a specialist in reimbursement, health economics, and health policy issues, has joined Abt Bio-Pharma Solutions, Inc. (ABS) as Senior Director, Reimbursement and Health Economics. Dr. Sullivan has more than 15 years of experience in industry and consulting and has led and contributed to a broad spectrum of successful projects, providing expertise and insight in private payer strategy, prospective and retrospective health economics studies, patient reported outcomes research, and registry and clinical trial study design and operations.

"We are very pleased to welcome Erin as a member of our senior team," said Steve Fosburg, President of ABS. "Our clients are increasingly faced with a wide variety of challenges to product success and the bottom line, including competitive pressures, generics/patent expiration, and unfavorable reimbursement/regulatory environments. Traditional approaches tend to be too one-dimensional to effectively manage these complex issues, which is why so many sponsors prefer ABS' brand of integrated, cross-disciplinary solutions. Erin's diverse experience and wide-ranging skill set is a perfect match."

Prior to joining ABS, Dr. Sullivan was a Director of Health Economics and Reimbursement at Boston Scientific Corporation. In this role, she led a team of researchers in providing strategic guidance and implementing reimbursement, health economic, and health policy initiatives to support a $700 million global business unit. Dr. Sullivan has also held research positions at The Lewin Group/Quintiles, Covance Health Economics and Outcomes Services, and the Beth Israel Hospital. Her work has been published in numerous peer-reviewed scientific healthcare journals including Pharmacoeconomics, Value in Health, Journal of Clinical Psychiatry, Arthritis Care and Research, and Urology.

Dr. Sullivan earned a Ph.D. in Health Services Research from the Johns Hopkins Bloomberg School of Public Health, a Master of Public Health from The George Washington University School of Hygiene and Public Health, and a Bachelor of Science in Psychology from Vanderbilt University.

The ABS team has provided integrated strategic, research, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries as well as through retrospective data analyses, models, and quantitative and qualitative research. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, and communicate the results to internal and external audiences. Primary service offerings include registries and other late-phase clinical studies, health economics and outcomes research, pricing and reimbursement, strategic commercialization services, and biometrics. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.

Abt Bio-Pharma Solutions, Inc.

CONTACT: Julia Altman, Director, Marketing of Abt Bio-Pharma Solutions,Inc., +1-781-372-6658, julia.altman@abtbiopharma.com

Web site: http://www.abtassociates.com/

Source: PRNewswire

More News in this Category